Annotation Detail
Information
- Associated Genes
- ABL1
- Associated Variants
- ABL1 ETV6-ABL1
- Associated Disease
- obsolete precursor B lymphoblastic lymphoma/leukemia
- Source Database
- CIViC Evidence
- Description
- An adult patient (82 yo) who presented with B-ALL (initial WBC of 183,000) with ETV6-ABL1 fusion was treated with dasatinib as a single agent after his chemotherapy had to be stopped due to toxicity. This resulted in morphological and cytogenetic remission after 2 weeks of treatment. Patient continued dasatinib daily plus 2 cycles of prednisolone (50 mg orally daily) for 4 weeks each. He remained in cytogenetic remission after 8 months of maintenance dasatinib. (See Supplementary Appendix 2, Page 11).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/6969
- Gene URL
- https://civic.genome.wustl.edu/links/genes/4
- Variant URL
- https://civic.genome.wustl.edu/links/variants/2575
- Rating
- 2
- Evidence Type
- Predictive
- Disease
- Precursor B Lymphoblastic Lymphoma/leukemia
- Evidence Direction
- Supports
- Drug
- Dasatinib
- Evidence Level
- C
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 25207766
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Dasatinib | Sensitivity | true |